Lead Product(s): Cannabinoids
Therapeutic Area: Neurology
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Solarvest BioEnergy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 04, 2020
Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares to Solarvest, which will enable Solarvest to fund the CBD Research Project.